JP5487117B2 - ニューロテンシン受容体３に由来するペプチドおよび精神疾患の治療におけるその使用 - Google Patents

ニューロテンシン受容体３に由来するペプチドおよび精神疾患の治療におけるその使用 Download PDF

Info

Publication number
JP5487117B2
JP5487117B2 JP2010538844A JP2010538844A JP5487117B2 JP 5487117 B2 JP5487117 B2 JP 5487117B2 JP 2010538844 A JP2010538844 A JP 2010538844A JP 2010538844 A JP2010538844 A JP 2010538844A JP 5487117 B2 JP5487117 B2 JP 5487117B2
Authority
JP
Japan
Prior art keywords
peptide
trek
mice
ntsr3
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010538844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505864A5 (enExample
JP2011505864A (ja
Inventor
マゼラ、ジャン
ペトロルト、オリヴィエ
ボルソット、マルク
オルトー、カトリーヌ
ヴィドマン、カトリーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université Côte d'Azur
Original Assignee
Centre National de la Recherche Scientifique
Université Côte d'Azur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Université Côte d'Azur filed Critical Centre National de la Recherche Scientifique
Publication of JP2011505864A publication Critical patent/JP2011505864A/ja
Publication of JP2011505864A5 publication Critical patent/JP2011505864A5/ja
Application granted granted Critical
Publication of JP5487117B2 publication Critical patent/JP5487117B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2010538844A 2007-12-21 2008-12-18 ニューロテンシン受容体３に由来するペプチドおよび精神疾患の治療におけるその使用 Active JP5487117B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07291602A EP2077278A1 (fr) 2007-12-21 2007-12-21 Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
EP07291602.6 2007-12-21
PCT/FR2008/001784 WO2009103898A1 (fr) 2007-12-21 2008-12-18 Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques

Publications (3)

Publication Number Publication Date
JP2011505864A JP2011505864A (ja) 2011-03-03
JP2011505864A5 JP2011505864A5 (enExample) 2012-02-16
JP5487117B2 true JP5487117B2 (ja) 2014-05-07

Family

ID=39304741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538844A Active JP5487117B2 (ja) 2007-12-21 2008-12-18 ニューロテンシン受容体３に由来するペプチドおよび精神疾患の治療におけるその使用

Country Status (7)

Country Link
US (1) US8252748B2 (enExample)
EP (2) EP2077278A1 (enExample)
JP (1) JP5487117B2 (enExample)
AT (1) ATE535543T1 (enExample)
CA (1) CA2709907C (enExample)
ES (1) ES2377489T3 (enExample)
WO (1) WO2009103898A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
CA2938019A1 (en) * 2014-01-27 2015-07-30 Centre National De La Recherche Scientifique Retro-inverso analogs of spadin display increased antidepressant effects
PT3380495T (pt) 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
FR3057267A1 (fr) 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR3057266B1 (fr) * 2016-10-11 2021-05-21 Centre Nat Rech Scient Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
US12662512B2 (en) 2019-10-22 2026-06-23 Genethon Chimeric polypeptides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037762A1 (en) * 1998-01-27 1999-07-29 Smithkline Beecham Plc Trek-1 like two pore potassium channel
DK1891966T3 (da) * 2002-12-20 2012-04-02 Lundbeck & Co As H Modulation af neurotrophinaktivitet; fremgangsmåde til screening
EP2077278A1 (fr) 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques

Also Published As

Publication number Publication date
US20110237515A1 (en) 2011-09-29
JP2011505864A (ja) 2011-03-03
CA2709907A1 (fr) 2009-08-27
EP2229408B1 (fr) 2011-11-30
ES2377489T3 (es) 2012-03-28
US8252748B2 (en) 2012-08-28
EP2077278A1 (fr) 2009-07-08
WO2009103898A1 (fr) 2009-08-27
CA2709907C (fr) 2016-11-08
EP2229408A1 (fr) 2010-09-22
ATE535543T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
Allette et al. Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain
JP6896050B2 (ja) ＴＡＴｋ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用
JP3771585B2 (ja) ＭＣＰ−１、ＭＩＰ−１αおよび／またはＲＡＮＴＥＳに結合可能なケモカインレセプターおよびその用途
EP2994157B1 (en) Tafa4 compounds and uses thereof for treating pain
JP2012501973A (ja) 痛みの治療に関する薬剤及び方法
JP2011505864A (ja) ニューロテンシン受容体３に由来するペプチドおよび精神疾患の治療におけるその使用
JP6640725B2 (ja) ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
JP2017507655A5 (enExample)
JP2019522989A (ja) ＴＡＴκ−ＣＤＫＬ５融合タンパク質、組成物、製剤、及びそれらの使用
Yin et al. RGS5 augments astrocyte activation and facilitates neuroinflammation via TNF signaling
TR201802849T4 (tr) Nörolojik hastalıkların tedavisinde veya teşhisinde kullanıma yönelik ilaç dağıtım sistemi.
JP5828345B2 (ja) うつ病治療のための併用剤
JP2002513380A (ja) コナントキンの使用
Trybus et al. MPP1-based mechanism of resting state raft organization in the plasma membrane. Is it a general or specialized mechanism in erythroid cells?
Fil et al. A broad upregulation of cerebral chemokine genes by peripherally-generated inflammatory mediators
US7132399B2 (en) Mammalian cell surface DNA receptor
JP5519702B2 (ja) 鎮痛を目的とする、ｔ型カルシウムチャンネルの新規拮抗薬である毒素の同定
KR100692226B1 (ko) 신규 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및 그 용도
FI3526244T3 (en) PEPTIDES DERIVED FROM NTSR3 PROPEPTIDE AND THEIR USE IN THE TREATMENT OF DEPRESSION
Weathington et al. The biology of CXC chemokines and their receptors
Rivera Rewarding Effects of Ethanol
KR101634440B1 (ko) AMPA 수용체 GluA1의 인산화 억제제를 포함하는 정신질환의 예방 또는 치료용 약학조성물
JP2008546691A (ja) 乾癬の病変内処置
JP2009520479A (ja) 溶解性ｉｌ−１７ｒｃ変異体及びそれらの使用
Järve Age-specific changes in regeneration potential in CNS: molecular analysis on animal model of traumatic spinal cord injury

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111226

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140224

R150 Certificate of patent or registration of utility model

Ref document number: 5487117

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250